Index

Note: page numbers in italics refer to figures and tables

accountability 82, 140–5, 146
collective 143–4, 145
institutional 144
moral 139
personal 67, 144–5
Activities of Daily Living Index (ADL) 120
adverse drug event 4–5
    computer surveillance method 178
    costs 186
    definitions 177–8
    fatalities 186
    methodology 178–9
    preventability 187
    reducing 188–9
    system failures 138
adverse drug reaction 1, 116, 134, 145, 175–7
    costs 186
    definitions 177–8
    drug compliance 181
    drug-related hospital admissions 182–4
    elderly patients 180, 182, 183
    general practice setting 181
    hospital setting 184–6, 243
    incidence 176–7, 183, 184–5
    information technology 231
    innocent ignorance as excuse 132–3
    malpractice costs 186
    medically-induced complication incidence 235
    methodology 178–9
    mortality 186
    non-compliance 184
    outpatients 179–82, 242
    patient population 179
    preventability 187
    probabilistic scaling methods 179, 182
    reducing 188–9
    severity 185–6
    surveillance methods 178–9, 181, 230
    systems analysis 232
    agency 140–5
    individual 141
    Agency for Health Care Policy and Research (AHCPR) 207
    Patient Outcomes Research Team (PORT) studies 215, 236
    AIDS provider safety 159
    public health interests 125
    Al-Ruhawi 6
    American College of Surgeons (ACS) Committee on Hospital
    Standardization 32
    Minimum Standards for Hospitals 32, 195
    American Hospital Association (AHA) Patient’s Bill of Rights 71
    American Medical Association (AMA) 9
    Code of Ethics (1847) 9, 11–12, 21, 22
    consultation clause 45, 46
    controversy 45–7
    medical education 27
    verbal communication 61
    Code of Ethics (1903) 25
    Council on Pharmacy and Chemistry 48
    amputation 41
    anesthesia 43
    reform of practice 65
animacular hypothesis 156
appendectomy 200
incidence 196
appraisal, negative of peers 24
appropriateness 214–15, 236
clinical assessment 215–19, 220
concensus methodology 214
cost–containment influence 223
economic efficiency influence 223
evidence-based approach 215
financial considerations 223
interpretation in clinical context 222–4
patient’s perspective 221–2
quality of life 222
societal dimension 224–5
value assessment 221
audit 30
error identification 233
unnecessary surgery 195
authorization, decisional 95
autonomy 57
common morality ethics 83–4
conflicts 84–5
during 1960s and 1970s 82
healing relationship 87–8
human health 73
personal 25
self-determination 69
as substantive good 73
violation for public health interests 125

bacteriology 157
Barr, David 62–4
Beauchamp, Tom 83–6, 107
Beecher, Henry 55–6, 64–5
beneficence 36
common morality ethics 83–4
conflicts 84–5
conservative medicine 43
duty 96
Engelhardt’s views 91
fiduciary model 96, 97
obligations 85–6
positive actions 5
prima cy 71
utilitarian concept 54, 55
utilitarian interpretation 82
see also nonmaleficence
benefit 41
maximization 43
positive obligation 96
principle 29–30

proportional calculation 43, 44
reasonable person account 122
skeptical empiricism 41
benefits administrators 82
Bigelow, Henry 156
Bigelow, Jacob 8
biomedical ethics 72, 83–6
biomedicine 52
bloodletting 39
skeptical view 40
Blue Cross and Blue Shield 197
breach of contract 101–2
Brown, John 39
calamel 7, 8, 11
depleting therapy 39
skeptical view 40
Canterbury v. Spence 54, 70
care
appropriateness 6
necessary 1
process breakdown 5
Carnegie Foundation for the Advancement of Teaching 28
causal agency 139
Center for Disease Control (CDC) 2
cesarean section 206
chilbed fever see puerperal fever
Childress, James 83–6
civil rights 65
clinical assessment, appropriateness 215–19, 220
clinical benefit/harm ratio 215
clinical harm, evidence regarding efficacy/effectiveness 217
clinical interventions
contraindicated 217–18, 219
desirability 219, 221–2
effectiveness 220–1
efficacy 220–1
equivocal 217, 219
highly indicated 217, 219
indicated/highly indicated 216–17, 219
non-indicated 218, 219
patient-centered outcome measures 220–1
possibly beneficial 216
sample plotting 220
clinical observation, empiricists 40
clinical pathways 106–7
Codman, Ernest 25, 29–33
der-end result system 195
hospital standardization 141–2
collective accountability 143–4, 145
collective agency model 143–4
comogenic harm 117
Index

conceptualization 123
culpable ignorance 134
drugs 187
duress 134-6
dimensional ethics 118
excuses 132
innocent ignorance 132-4
lack of sufficient resources 135
mistakes 136-40
moral evaluation 123
non-preventability 136
pharmacology training in reduction 235
prevention model 166-7
scope 119-20
therapeutic research 127
types 145-6
comiogenic illness 122, 123
commission, harms of 43, 86
Committee on Medical Research (CMR) 48-9
common morality ethics 83-4
Communicable Diseases Center (CDC), Hospitals Infections Branch 158
communication breakdown 5
doctor-patient 61
due care 107-8
failures 139-40
information technology 231
patient involvement 110
patient well-being 109-10
provider-patient 107-10
verbal 61
community, Engelhardt’s views 93, 94
confidentiality breach 125-6
violation for public health interests 125
conflict resolution, ethical guides 223-4
conservative medicine 42-3
consumer advocacy literature 3
consumerism, free market 89, 94
containment, resistance to idea 155
continuous quality improvement (CQI) 111, 141-5, 165
moral responsibility attribution 143-4
quality assessment model 142
system-focused 231-2
contract models 96
cost-benefit analysis (CBA) 103, 164
cost-containment 223
cost-control 82
physicians 107
cost-effectiveness analysis (CEA) 103, 164
cost-worthiness 223
cultural beliefs 110
deception, paternalistic 69
decision-making
authority for 213
informed consent 74, 222
institutional controls 135
patient involvement 110
patient participation 82
patient values/preferences 116
prerogative of patient 130
progress 107-10
surgical practice 208
defense services 206
defensive medicine 27, 205-6
delivery of care 110-11
deflective therapy 38-9
diagnosis, Hippocratic 37
diagnostic technologies 21
diagnostic-related groups (DRG) 163
coordination 104
disclosure
benefits/harm 69
due care 108
duty of 68
potentially harmful effects 108-9
professional standard 70
standards of reasonable patient 70
therapeutic justification 69
disease concept 122
humoral theory 38
‘do no harm’ concept 81
conditioning 123
healing relationship 88
fiduciary nature 97
moral obligation 85
positive obligations 96
doctor-patient relationship
research community benefits 49-50
scientific medicine 53
shift of decisional authority 95
drug administration errors, systems analysis 235-6
drug compliance 188
Drug Import Law (1848) 175
drug interaction programs, computerized 187
drug-related hospital admissions 182-4, 244
drugs
administration errors 188
complication frequency 176
computerized ordering systems 188
regulation in public policy initiatives 176
testing efficacy 50
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>due care 100, 145</td>
</tr>
<tr>
<td>accountability 102</td>
</tr>
<tr>
<td>advocacy role of physician 106</td>
</tr>
<tr>
<td>communication 107–8</td>
</tr>
<tr>
<td>delivery of care 110–11</td>
</tr>
<tr>
<td>disclosure 108</td>
</tr>
<tr>
<td>divided standard 105</td>
</tr>
<tr>
<td>informed consent 107–8</td>
</tr>
<tr>
<td>provider–patient communication 107–10</td>
</tr>
<tr>
<td>treatment selection 106</td>
</tr>
<tr>
<td>duress 134–6</td>
</tr>
<tr>
<td>duty of care, therapeutic risks 101</td>
</tr>
<tr>
<td>economic efficiency 103, 223</td>
</tr>
<tr>
<td>education 9</td>
</tr>
<tr>
<td>evidence-based 235</td>
</tr>
<tr>
<td>goals 128</td>
</tr>
<tr>
<td>iatrogenic harm limiting 233–6</td>
</tr>
<tr>
<td>justification of harm 126–8</td>
</tr>
<tr>
<td>pharmacology 188–9</td>
</tr>
<tr>
<td>public policy 128</td>
</tr>
<tr>
<td>self-criticism orientation 233</td>
</tr>
<tr>
<td>teaching strategies 127–8</td>
</tr>
<tr>
<td>empiricism 40–1</td>
</tr>
<tr>
<td>statistical 42–3</td>
</tr>
<tr>
<td>employers</td>
</tr>
<tr>
<td>economic goals 128</td>
</tr>
<tr>
<td>medical program sponsorship 197</td>
</tr>
<tr>
<td>end-result system 29–31, 195</td>
</tr>
<tr>
<td>Engelhardt HT 89</td>
</tr>
<tr>
<td>epidemiologic surveillance 159–60</td>
</tr>
<tr>
<td>epistemic authority of medical science 47</td>
</tr>
<tr>
<td>epistemology</td>
</tr>
<tr>
<td>humoral 38</td>
</tr>
<tr>
<td>reductionist 44</td>
</tr>
<tr>
<td>scientific 72</td>
</tr>
<tr>
<td>errors</td>
</tr>
<tr>
<td>evaluation 137</td>
</tr>
<tr>
<td>identification mechanisms 233</td>
</tr>
<tr>
<td>preventable 137</td>
</tr>
<tr>
<td>evidence</td>
</tr>
<tr>
<td>correlation framework 216</td>
</tr>
<tr>
<td>hierarchical ranking of quality 216</td>
</tr>
<tr>
<td>for valid/reliable standards 101</td>
</tr>
<tr>
<td>evidence-based medicine 214–18, 235</td>
</tr>
<tr>
<td>evidentiary judgments 215–16</td>
</tr>
<tr>
<td>expert knowledge 47</td>
</tr>
<tr>
<td>expertise, social legitimation 47</td>
</tr>
<tr>
<td>Federal Food and Drug Act (1906) 175</td>
</tr>
<tr>
<td>Federal Food, Drug and Cosmetic Act (1938) 48, 175</td>
</tr>
<tr>
<td>fee-for-service</td>
</tr>
<tr>
<td>nosocomial infection costs 163</td>
</tr>
<tr>
<td>surgical utilization 202</td>
</tr>
<tr>
<td>system 128–9</td>
</tr>
<tr>
<td>feminism 65</td>
</tr>
<tr>
<td>fetal monitoring, defensive use 206</td>
</tr>
<tr>
<td>fiduciary, healer’s role 88–9</td>
</tr>
<tr>
<td>fiduciary duty of physician 68</td>
</tr>
<tr>
<td>fiduciary models 96</td>
</tr>
<tr>
<td>fiscal resources</td>
</tr>
<tr>
<td>distribution 131–2</td>
</tr>
<tr>
<td>scarcity 136</td>
</tr>
<tr>
<td>Flexner, Abraham 195</td>
</tr>
<tr>
<td>Food and Drug Administration (FDA)</td>
</tr>
<tr>
<td>drug efficacy testing 50</td>
</tr>
<tr>
<td>MEDWatch program 134</td>
</tr>
<tr>
<td>regulation 134</td>
</tr>
<tr>
<td>free market transactions 89, 94</td>
</tr>
<tr>
<td>futility, societal meanings 225</td>
</tr>
<tr>
<td>gentlemanly honour tradition 24–5</td>
</tr>
<tr>
<td>germ theory, hostility to 156</td>
</tr>
<tr>
<td>government regulation of research 54–5</td>
</tr>
<tr>
<td>governmental agencies 2</td>
</tr>
<tr>
<td>Hammurapi, Code of 6, 7</td>
</tr>
<tr>
<td>hand washing 154</td>
</tr>
<tr>
<td>harmful acts</td>
</tr>
<tr>
<td>excusability 123–4, 132–40</td>
</tr>
<tr>
<td>justifiability 123–32</td>
</tr>
<tr>
<td>harms</td>
</tr>
<tr>
<td>of commission 43, 86</td>
</tr>
<tr>
<td>of omission 8, 43, 86</td>
</tr>
<tr>
<td>prohibition against 91</td>
</tr>
<tr>
<td>proportional calculation 43, 44</td>
</tr>
<tr>
<td>secular pluralist morality 91–2</td>
</tr>
<tr>
<td>therapeutic intervention 8</td>
</tr>
<tr>
<td>healing action 88</td>
</tr>
<tr>
<td>healing relationship ‘do no harm’ 88</td>
</tr>
<tr>
<td>fiduciary nature 86–9</td>
</tr>
<tr>
<td>health</td>
</tr>
<tr>
<td>humoral theory 38</td>
</tr>
<tr>
<td>liberty 74</td>
</tr>
<tr>
<td>health care</td>
</tr>
<tr>
<td>access concerns 224</td>
</tr>
<tr>
<td>costs 100</td>
</tr>
<tr>
<td>delivery 94, 110–11</td>
</tr>
<tr>
<td>dimensions of quality 123</td>
</tr>
<tr>
<td>Engelhardt’s views 90–1</td>
</tr>
<tr>
<td>evidence-based standards 100</td>
</tr>
<tr>
<td>financing 82, 94</td>
</tr>
<tr>
<td>fiscal scarcity 136</td>
</tr>
<tr>
<td>managed 129</td>
</tr>
<tr>
<td>new economics 124</td>
</tr>
<tr>
<td>physicians role in economics 128</td>
</tr>
<tr>
<td>professionals and occupational infection 160</td>
</tr>
<tr>
<td>providers, positive obligations 96</td>
</tr>
<tr>
<td>public standard 225</td>
</tr>
</tbody>
</table>
Index

quality 100
quality evaluation and patient outcomes 165–6
resources
justice in distribution 131–2
lack of sufficient 135
social conception of function 121
Health Education and Welfare (HEW) Task Force on Prescription Drugs 2
Health Maintenance Organizations (HMOs) 82
surgical options 204–5
health plan administrators, decisional authority 95
hepatitis B
provider safety 159
public health interests 125
heroic medicine 8, 39–40, 41
Hill-Burton Act (1946) 62
Hippocratic Corpus 6, 53, 83
Hippocratic era 37
physician status 37–8
Hippocratic injunction 81
do no harm 7
HIV infection, public health interests 125
holistic perceptions 38
holistic rationalism 39–40
Holmes, OW 154
homeopathy 41–2
hospital
access 62
admission 21
drug-related 182–4, 244
efficiency
assessment 31, 131
criteria 29–30
evaluation 33
epidemiology 157–62, 159
infection control programs 161–2
oversight system 25
quality assessment 131
quality management in infection control 158–9
services and risk profile 166
hospitalism 156
hospitalized patients, deleterious effects 66
human health, autonomy 73
human subjects research 54–7
informed consent 127
justification 126–8
non-therapeutic 118–19
patient welfare 55–6
protection 126
regulation 126
therapeutic 119
humoral theory 37
humoralism 36, 38
hysterectomy 196
iatrogenesis 3
cultural 73
iatrogenic complications
hospital admissions 242
hospital setting 241
prospective study 65
iatrogenic effects, libertarian theory 92
iatrogenic harm
clinical evaluation 120–1
concepts 117–20
definition in 1960s 66
education in limitation 233–6
limiting 230–7
object 117–19
patient evaluation 121–3
reasonable person account 122
scope 119–20
source 117
treatment underuse/overuse 237
see also commiogenic harm
iatrogenic illness 1
Barr and Moser’s description 62–3
changing definition 4
concept 115–16
definitions 116
etiology 62
governmental agencies 2
medical malpractice 2
post World War II 62
preventability 4–5
profession view 1
severity 4
utilitarian definition 73–4
utilitarian justification 62
Illich, Ivan 3–4, 73, 74
illness
concept 122
fact of 86
holistic interpretation 61
indemnity plans 197
infallibility ethos, overcoming 232–4
infection control
epidemiologic surveillance 159–60
hospital quality management 158–9
movement 157–62
infection control programs
hospitals 161–2
resources 163
infection surveillance 159–60
information technology 231
informed consent 67–72
appropriateness classifications 219
# Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>informed consent (cont.)</td>
<td>54</td>
</tr>
<tr>
<td>Canterbury v. Spence</td>
<td>54</td>
</tr>
<tr>
<td>clinical uncertainty</td>
<td>234</td>
</tr>
<tr>
<td>conflict avoidance</td>
<td>222</td>
</tr>
<tr>
<td>decision-making</td>
<td>74, 222</td>
</tr>
<tr>
<td>due care</td>
<td>107, 8</td>
</tr>
<tr>
<td>financial restriction disclosure</td>
<td>224</td>
</tr>
<tr>
<td>human subjects research</td>
<td>127</td>
</tr>
<tr>
<td>patient authority</td>
<td>64</td>
</tr>
<tr>
<td>surgical innovations</td>
<td>207</td>
</tr>
<tr>
<td>institutional controls, decision-making</td>
<td>135, 15</td>
</tr>
<tr>
<td>institutional policy, disclosure to patient</td>
<td>108</td>
</tr>
<tr>
<td>Institutional Review Board (IRB)</td>
<td>56–7</td>
</tr>
<tr>
<td>instruments, development</td>
<td>44–5</td>
</tr>
<tr>
<td>insurance</td>
<td></td>
</tr>
<tr>
<td>commercial</td>
<td>197</td>
</tr>
<tr>
<td>employer plans</td>
<td>94–5</td>
</tr>
<tr>
<td>growth of industry</td>
<td>10</td>
</tr>
<tr>
<td>hospitalization</td>
<td>62</td>
</tr>
<tr>
<td>malpractice</td>
<td>26</td>
</tr>
<tr>
<td>Jefferson, Thomas</td>
<td>8–9</td>
</tr>
<tr>
<td>job design, errors</td>
<td>138</td>
</tr>
<tr>
<td>Joint Commission for the Accreditation of Healthcare Organizations (JCAHO)</td>
<td>142, 165</td>
</tr>
<tr>
<td>Joint Commission on Accreditation of Hospitals (JCAH)</td>
<td>33, 71, 158</td>
</tr>
<tr>
<td>justice</td>
<td></td>
</tr>
<tr>
<td>common morality ethics</td>
<td>84</td>
</tr>
<tr>
<td>conflicts</td>
<td>84–5</td>
</tr>
<tr>
<td>distributive</td>
<td>125</td>
</tr>
<tr>
<td>laboratory science</td>
<td>44–5</td>
</tr>
<tr>
<td>learning, evidence-based</td>
<td>235</td>
</tr>
<tr>
<td>legal liability, defensive medicine</td>
<td>205–6</td>
</tr>
<tr>
<td>libertarian theory</td>
<td>89–95</td>
</tr>
<tr>
<td>trust conveying</td>
<td>93</td>
</tr>
<tr>
<td>liberty</td>
<td>74</td>
</tr>
<tr>
<td>licensure, professional regulatory control</td>
<td>48</td>
</tr>
<tr>
<td>life support withdrawal</td>
<td>72</td>
</tr>
<tr>
<td>Lister, Joseph</td>
<td>155, 156</td>
</tr>
<tr>
<td>Logerfo JP</td>
<td>204</td>
</tr>
<tr>
<td>managed care plans</td>
<td>129</td>
</tr>
<tr>
<td>cost-savings</td>
<td>135</td>
</tr>
<tr>
<td>funding denial</td>
<td>136</td>
</tr>
<tr>
<td>patient risk</td>
<td>135</td>
</tr>
<tr>
<td>prospective payment</td>
<td>163–4</td>
</tr>
<tr>
<td>medical admissions</td>
<td>21</td>
</tr>
<tr>
<td>medical Art vs. Nature</td>
<td>7</td>
</tr>
<tr>
<td>medical benefit plans</td>
<td>62</td>
</tr>
<tr>
<td>medical consumerism</td>
<td>74–5</td>
</tr>
<tr>
<td>medical education</td>
<td></td>
</tr>
<tr>
<td>Flexner’s survey (1910)</td>
<td>195</td>
</tr>
<tr>
<td>professional regulatory control</td>
<td>48</td>
</tr>
<tr>
<td>reform</td>
<td>27–9</td>
</tr>
<tr>
<td>medical ethics, free-market control</td>
<td>89–95</td>
</tr>
<tr>
<td>medical fallibility</td>
<td>234</td>
</tr>
<tr>
<td>medical injuries, no-fault compensation  schemes</td>
<td>142–3</td>
</tr>
<tr>
<td>medical knowledge</td>
<td>53</td>
</tr>
<tr>
<td>flawed</td>
<td>133</td>
</tr>
<tr>
<td>lack of, in patients</td>
<td>53–4</td>
</tr>
<tr>
<td>quality improvement research</td>
<td>168</td>
</tr>
<tr>
<td>medical malpractice</td>
<td>2, 10, 25–7, 141</td>
</tr>
<tr>
<td>bad outcome disclosure</td>
<td>234</td>
</tr>
<tr>
<td>professional standard violation</td>
<td>234</td>
</tr>
<tr>
<td>medical morality</td>
<td>83</td>
</tr>
<tr>
<td>Medical Nemesis</td>
<td>72–3</td>
</tr>
<tr>
<td>Medical Outcomes Study (MOS) Short Form</td>
<td>120</td>
</tr>
<tr>
<td>medical profession</td>
<td></td>
</tr>
<tr>
<td>accountability in 1960s and 1970s</td>
<td>67</td>
</tr>
<tr>
<td>authority</td>
<td>74</td>
</tr>
<tr>
<td>consolidation</td>
<td>22–5</td>
</tr>
<tr>
<td>experimental science impact</td>
<td>11</td>
</tr>
<tr>
<td>prestige</td>
<td>74</td>
</tr>
<tr>
<td>medical societies, local</td>
<td>25–7</td>
</tr>
<tr>
<td>medication errors</td>
<td>137, 138</td>
</tr>
<tr>
<td>communication failures</td>
<td>139</td>
</tr>
<tr>
<td>medicinal compounds, professional</td>
<td></td>
</tr>
<tr>
<td>regulatory control</td>
<td>48</td>
</tr>
<tr>
<td>medicine</td>
<td></td>
</tr>
<tr>
<td>act of</td>
<td>88</td>
</tr>
<tr>
<td>as agent of persons</td>
<td>90</td>
</tr>
<tr>
<td>conservative</td>
<td>42–3</td>
</tr>
<tr>
<td>evidence-based</td>
<td>214–18, 235</td>
</tr>
<tr>
<td>MEDWatch program</td>
<td>2</td>
</tr>
<tr>
<td>Meigs, C</td>
<td>154</td>
</tr>
<tr>
<td>mercurous chloride see calomel</td>
<td></td>
</tr>
<tr>
<td>mistakes, harmful</td>
<td>136–40</td>
</tr>
<tr>
<td>moral accountability</td>
<td>139</td>
</tr>
<tr>
<td>moral authority, agreements between</td>
<td></td>
</tr>
<tr>
<td>people</td>
<td>89</td>
</tr>
<tr>
<td>morality</td>
<td></td>
</tr>
<tr>
<td>personhood requirement</td>
<td>90</td>
</tr>
<tr>
<td>secular pluralist</td>
<td>91–2</td>
</tr>
<tr>
<td>morbidity</td>
<td>120</td>
</tr>
<tr>
<td>Morreim, EH</td>
<td>105–6, 131</td>
</tr>
<tr>
<td>mortality</td>
<td>120</td>
</tr>
<tr>
<td>due to drug administration</td>
<td>245</td>
</tr>
<tr>
<td>Moser, Robert</td>
<td>4, 62–4</td>
</tr>
<tr>
<td>mutual respect</td>
<td>90</td>
</tr>
<tr>
<td>National Institutes of Health (NIH)</td>
<td>49</td>
</tr>
<tr>
<td>research</td>
<td>49–50, 56</td>
</tr>
<tr>
<td>National Welfare Rights Organization (NWRO)</td>
<td>71</td>
</tr>
<tr>
<td>natural healers</td>
<td>41–2</td>
</tr>
<tr>
<td>Nazi researchers</td>
<td>54–5</td>
</tr>
</tbody>
</table>
Index

negligence, tort law 141
Nightingale, Florence 156–7
nihilism, therapeutic 42
no-fault compensation 142–3
medical injuries 234
nosocomial infection 170
quality improvement research 170
non-preventable harm 136
nondisclosure
due care justification 110
therapeutic privilege 109
nonmaleficence 36, 42
common morality ethics 84
conflicts 84–5
conservative medicine 43
forbearance 85
nondisclosure justification 109
obligations 85–6
permission principle 92
primacy 71
utilitarian interpretation 82
see also beneficence
nosocomial infection 122, 145, 153
active surveillance techniques 160–1
autonomy limitations 167
control 154
comiogenic harm prevention model 166–7
cost-effectiveness 162–5
economic justification 164
financial incentive 164
medical harm prevention 164
quality improvement 165–6
data confidentiality 167–8
ethical issues 167–70
incidence 157–8, 158
medical devices 161
moral dilemmas 167
no-fault compensation 170
precautionary measures 160
preventable 161
privacy limitations 167
public right to knowledge 167–8
public safety concerns 167
reimbursement of treatment costs 163
surveillance 159–62
active continuous 166
effectiveness 234
intensive 166–7
passive voluntary 166
surveillance strategies 231
transmission source information 168
obstetric service provision 206
occupational infection 160
omission, harms of 8, 43, 86
organ transplantation, allocation of
organisms 132
outcome assessment 29, 30, 31, 120
paraclinical 120
quality of life 120
outcome measures, patient-centered 220–1
outcomes
health care quality evaluation 165–6
research 129–30
ovaries, surgical removal 196
pain minimization 43
Pasteur, Louis 154, 155
paternalism 36
charitable 51–2
deception 69
patient autonomy 57
professionalism 67
research 51
scientific medicine 52
therapeutic 54
patient
access to information 168, 169
articulation of benefits/harms 95
assessment 30
objective 25–6
authority in informed consent 64
evaluation of harm 121–3
fundamental liberty 223
health care choice 94–5
hospitalization 66
individual evaluation of harm 122
libertarian theory 92–3
moral commitment of profession to
avoid harm 224
privacy violation for public health
interests 125
procedure recommendation for care
215
protection tension with
self-determination 69
quality of care 146
records 30
refusal of undesired care 223
responsibility for health 74
rights 63–7, 74
legally binding bills 71
movement 83, 127
risk in managed care plans 135
self-determination 67
values in medical decision-making 70
waiving of right of access to research
records 169
welfare
human subjects research 55–6
and practice standards 103
well-being and communication 109–10
patient-centered ethic 122
payment
prospective 164
retrospective 163
peer review 233
Pellegrino, Edmund 86-9, 96-7
Percival, Thomas 24
perceptibility of doctors 232
permission principle 90, 91
nonmaleficence 92
Pernick, Martin 40
personhood 90
pharmacology
physician education 188-9
training 188
pharmacotherapy, potential dangers 176
physician
act of profession 87
advocacy 130
obligations 224
clinical pathways 106-7
competing claims on loyalty 124
cost control 107
divided standard of due care 105
drug information sources 188
duties to other patients 125
economic advocate role 129
effectiveness 47
errors 137-8
fidelity to patient 135
fiduciary duty 68
financial duress 135, 136
financial gatekeeper role 136
financial incentives 203-5
financial viability of hospital 130
fiscal accountability 132
health care economics 128
individual performance 232
innocent ignorance as excuse 133
moral agents 224
moral authority 12
moral responsibility 12
obligation to patients 23-4, 124
patient care decisions 223
practice guidelines 106-7
primary agent of quality 140
resource duties 105
role in puerperal fever transmission 153-5
physician–poisoner 6-7
Pliny the Elder 6
policy makers, system failure 138
political forces 8
polypharmacy 176
adverse drug reaction 180
practice guidelines 106-7
practice standards 102, 103
prescription drugs

Index

borrowing 187
compliance 188
expenditure 175
sales 62
use 175
Principles of biomedical ethics 83-6
profession
act of 87
self-regulation 50
professional interests 23
professional organization 26
professional self-criticism ethos 233
professionalism model 233
Progressive era 47
proportional calculus 43
provider–patient communication 107-10
public health interests 125-6
puerperal fever 153
physician role in transmission 153-5
quackery, condemnation 23
quality 140-5
physician as primary agent 140
see also continuous quality improvement (CQI)
quality assurance (QA) 140-1
procedures 5
quality assurance (QA) program 165
infection control 163, 165
risk management 165
quality improvement research 167-70
medical knowledge 168
no-fault compensation 170
patient waiving of rights to records 169
quality of life 120
appropriateness of procedure 222
health-related 122
quality management programs 142
Quinlan, Karen Ann 72
RAND Health Services Utilization Study 201, 202-3, 204, 214-15
randomization, ethical challenges 214
randomized controlled trials 214
reductionism 44
research
clinical 49-50
development 48-9
government regulation 54-5
informed consent 67
justification of harm 126-8
non-therapeutic 118-19
outcomes 129-30
risk determination 51
risk disclosure 50
subject consent 51
Index

therapeutic 118
see also human subjects research; quality improvement research
researcher, goals 119

resources
control in treatment selection 105
fiscal 131–2, 136
infection control programs 163
lack and iatrogenic harm 135
physician’s duties 105
stewardship 107
surgical 200
retrospective payment, nosocomial
infection costs 163

risk
appropriateness concept 213–14
avoidance 206
reduction 206

Rosenberg, Charles 38
Rothman, David, 50, 52, 56
Rush, Benjamin 8, 39, 40–1

Salgo v. Leland Stanford Jr. 68, 69, 70
Schimmel, Elihu 65
Schloendorff v. Society of New York Hospitals 68

science, social legitimation 49
scientific epistemology 52
scientific expertise, authority 47–51
scientific knowledge, model of professionalism 233
scientific medicine 22, 45, 46
ascendancy 53
development 10–11, 12
doctor–patient relationship 53
paternalism 52
social legitimation 53
therapeutic promise 47–8
second opinion programs 198
self-care 73
self-criticism, professional 233
self-decision, patient’s right 107
self-determination 67
patient autonomy 69
patient’s right 68

tension with patient protection 69
self-regulation of profession 50
self-scrutiny 67
Semmelweis, I 153–4
Sickness Impact Profile (SIP) 120
Simpson, Sir James 155–6
Sims, JM 8
skepticism, therapeutic 40–1, 74–5
social disillusionment 65
Spitzer Quality of Life Index 120
standard of medical expertise (SME) 105

standard of resource use (SRU) 105

standards
establishment 101–4
evidence-based 100
professional practice 102
reliable 101
valid 101

staphylococcal infection pandemic 158

Starr, Paul 49, 74
statistical techniques 10–11
suffering, minimization 43
surgeons, numbers 197
surgery
appropriateness 208
asepsis 157
death rate 155–6
surgery, unnecessary 118, 139, 145,
194–208
audit 195, 196
curbing 196–9
definition 199
demand side 205
financial incentives 203–5
geographic variations 199–202
historical antecedents 195
incidence 203
medical need manifestations 205
national rate 198
supply side 205
surgical resources 200
tissue review 196
surgical admissions 21
surgical innovations 207
surgical practice
decision-making 208
knowledge base 206–8
licensing agencies 207–8
surgical rate variation 2–3
surgical second opinion 197
programs (SSOPs) 198, 202
surgical treatment
appropriateness 201
professional uncertainty over indications 201
surgical utilization
control 201–2
fee-for service 202
regional variation 200
surveillance
active 233
strategies 230–1

system failure 138

checks 139
follow-up 139
policy makers 138
review 139
Index

systems analysis  231–2
  drug administration errors  235–6
tartar emetic, skeptical view  40
therapeutic efficacy  10
  assessment  12
  eighteenth/early nineteenth century  38–9
therapeutic intervention, harms  8
therapeutic moderation  42–3
therapeutic nihilism, rejection by Barr and Moser  64
therapeutic privilege  69
  nondisclosure  109
therapeutic risks, duty of care  101
therapeutic skepticism  40–1, 74–5
therapeutics education/research  235
third-party payers  100, 197
  cost-worthiness of treatments  223
  economic goals  128
  standards promulgation  102
Thomasma DC  88–9, 96–7
tissue review  196
Todd, Donald  64–5
tonsillectomy  198–9
  geographic variations  200
  social status  205
tort law  141
  treatment  141
  evidentiary basis  236
  experimental evidence  236
  informed consent  67–8
  unnecessary  1
  treatment decisions  104–5
  malpractice claims  26–7
  treatment selection  104–7
  control of resources  105
  due care  106
  technological resources  105
  triage situation  125

US Preventive Services Task Force  216

utilitarianism
  human subjects research justification  127
  justification of iatrogenic illness  62
  utilization decisions  213

  value assessment, appropriateness  221
  values
    appropriateness concept  213–14
    cost-containment  223
    economic efficiency  223

Warner, JH  45

yellow fever epidemic (1793)  39